R&D Systems™ Human PlGF-4 Recombinant Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.
Manufacturer: R&D Systems™ 8987PL025
DescriptionThe Recombinant Human PlGF-4 Protein is derived from HEK293. The Recombinant Human PlGF-4 Protein has been validated for the following applications: Bioactivity.
|Human embryonic kidney cell, HEK293-derived Leu19-Arg242|
|Observed M.W.: 35-40kDa, reducing conditions, Theoretical M.W.: 25kDa|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.|
|Measured by its binding ability in a functional ELISA. When Recombinant Human VEGF R1/Flt-1 Fc Chimera, aa 27-328 is immobilized at 0.5μg/mL, 100μL/well, the concentration of Recombinant Human PlGF-4 that produces 50% of the optimal binding response is approximately 4-24ng/mL.|
|>85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining|
|Human embryonic kidney cell,HEK293-derived human PlGF-4 protein Leu19-Arg242|
|<0.10 EU per 1μg of the protein by the LAL method.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok